Terazosin polymorph and pharmaceutical composition

Details Terazosin polymorph and pharmaceutical composition Terazosin polymorph and pharmaceutical composition

1994-01-06

1994-11-08

Tsang, Cecilia

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

544291, A61K 31505, C07D23984

Patent

active

053627300

ABSTRACT:
A process for preparing a novel anhydrous crystalline polymorph of anhydrous 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl) piperazine monohydrochloride comprises contacting the known amorphous, crystalline dihydrate, or crystalline anhydrous form I of the compound with a polar organic solvent.

REFERENCES:
patent: 4026894 (1977-05-01), Winn et al.
patent: 4112097 (1978-09-01), Winn et al.
patent: 4251532 (1981-02-01), Roteman
patent: 5212176 (1993-05-01), Kyncl et al.

Affiliated with

Also associated with

Rating

Terazosin polymorph and pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Terazosin polymorph and pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Terazosin polymorph and pharmaceutical composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1782638